None listed
Conditions
Brief summary
looking at effectiveness of treating persistent cough with a medication
Interventions
300 mg of oral Neurontin once per day, then increased to 600mg/d for second day, then 900mg/d for third day upto maximum tolerable dose of 1800mg/day for ten weeks.
Sponsors
Hunter New England Area Health Service
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Persistent non-productive cough of more than 8 weeks duration, Male or female between ages of 18 and 80 years, Non-smoker or ex-smoker with less than 10 pack years, To have been well during the 4 weeks prior to study entry, Informed consent obtained.
Exclusion criteria
Productive cough, Current smoker, Smoking history >10 pack years, Pregnancy/breast feeding, Other respiratory disease, eg: bronchiectasis, COPD. Inability to attend study visits Respiratory tract infection during month prior to randomisation Impaired liver function at Visit 1 as shown by Aspartate aminotransferase (AST), an enzyme normally present in liver and heart cells and alanine aminotransferase (ALT). If the liver is injured, the liver cells spill the enzymes into blood, raising the enzyme levels in the blood and signaling liver damage. Therefore, an AST, ALT, alkaline phosphatase or total bilirubin greater than 2 times the upper limit of normal will exclude a participant.
Outcome results
None listed